Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906862 | 1.00 | EGFR (0.53) | EGFRNAMPTMGAMTDP1HCAR2 | |
| SCHEMBL30533141 | 0.86 | EGFR (0.53) | EGFRTDP1HCAR2CSNK2A2CSNK2B | |
| SCHEMBL12466410 | 0.86 | EGFR (0.53) | EGFRTDP1HCAR2CSNK2A2CSNK2B | |
| SCHEMBL5676295 | 0.84 | EGFR (0.56) | EGFRNAMPTPIK3CDPIK3CACSNK2A2 | |
| SCHEMBL25920350 | 0.84 | EGFR (0.51) | EGFRNAMPTMGAMPIK3CDPIK3CA | |
| SCHEMBL29649950 | 0.84 | EGFR (0.56) | EGFRNAMPTPIK3CDPIK3CACSNK2A2 | |
| SCHEMBL30478693 | 0.83 | EGFR (0.47) | EGFRNAMPTMGAMPIK3CDPIK3CA | |
| SCHEMBL27881435 | 0.83 | EGFR (0.54) | EGFRNAMPTPIK3CDPIK3CACSNK2A2 | |
| SCHEMBL5495516 | 0.82 | GRIK1 (0.48) | EGFRTDP1PIK3CDPIK3CACSNK2A2 | |
| SCHEMBL27866209 | 0.81 | EGFR (0.49) | EGFRNAMPTMGAMTDP1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117050300-A | Polylysine-based polymer adjuvant material, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2023-11-14 | — | — | CN | claimed |
| CN-113603886-A | Polyethyleneimine derivative and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2021-11-05 | — | — | CN | claimed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | claimed |
| CN-101111487-A | Processes for producing 4-aminoquinazolines | VERTEX PHARMA (US) | 2008-01-23 | — | — | CN | claimed |
| EP-1828150-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | Vertex Pharmaceuticals Incorporated (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | claimed |
| WO-2006066044-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | claimed |
| CN-1537105-A | Quinazolines useful as MMP-13 inhibitors | ��������ʲ��������ι�˾ | 2004-10-13 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-119529132-A | Modified chitosan derivative, nano-particles, preparation method and application | 苏州大学 | 2025-02-28 | — | — | CN | disclosed |
| WO-2005058326-A1 | USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| EP-0944629-B1 | BIARYL-PYRIDOQUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | AMERICAN CYANAMID CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5914327-A | Biaryl-pyridoquinazolinone derivatives as anti-cancer agents | AMERICAN CYANAMID COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | CACNA1I, CACNA1G, CACNA1B | EGFR 4393/4885NAMPT 1138/4885MGAM 4710/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | EGFR 2563/4885NAMPT 2533/4885MGAM 152/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | EGFR 1008/4885NAMPT 4738/4885MGAM 863/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | EGFR 58/4885NAMPT 4806/4885MGAM 1716/4885 |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | EGFR 107/4885NAMPT 1870/4885MGAM 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.